Table 1.
Effects of panobinostat (Pan) on MK-1775 anti-leukemic sensitivity in diagnostic AML blasts
| MK-1775 IC50 (nM) in the absence or presence of panobinostat |
|||||
|---|---|---|---|---|---|
| AML patient samples | Panobinostat IC50 (nM) | 0 nM Pan | 5 nM Pan | 10 nM Pan | 20 nM Pan |
| AML#0 | 27.0 | 5996.5 | 2506.0 (0.61) | 1408 (0.54) | 157.1 (0.77) |
| AML#1 | 16.7 | 2448.5 | 684.7 (0.58) | 200.7 (0.68) | ND |
| AML#2 | 34.9 | 3204.0 | 1682.0 (0.66) | 1156.0 (0.65) | 925.0 (0.86) |
| AML#3 | 55.2 | 461.0 | 383.6 (0.92) | 307.4 (0.85) | 236.4 (0.87) |
| AML#4 | 53.3 | 844.0 | 591.3 (0.79) | 734.0 (0.70) | 262.2 (0.69) |
| AML#5 | 14.0 | 948.3 | 449.2 (0.83) | 130.1 (0.85) | ND |
| AML#6 | 34.6 | 233.7 | 168.3 (0.86) | 139.8 (0.88) | 113 (1.05) |
| AML#7 | 26.3 | 325.0 | 244.5 (0.94) | 186.6 (0.95) | 67.6 (0.97) |
| AML#8 | 36.1 | 887.9 | 651.6 (0.87) | 528.3 (0.86) | 302.7 (0.89) |
| AML#10 | 25.4 | 439.7 | 309.6 (0.90) | 210.8 (0.87) | 91.9 (1.00) |
| AML#13 | 17.0 | 3579.2 | 657.2 (0.47) | 396.8 (0.70) | ND |
Note: IC50s are presented as mean of duplicates from one experiment. Numbers in the parentheses represent the combination index values. CI<0.9 indicates synergistic, 0.9<CI<1.1 indicates additive, and CI>1.1 indicates antagonistic anti-leukemic interactions. ND - not determined. AML#4, AML#5, and AML#7 were derived from patients at relapse. The rest of the primary AML patient samples were derived from patients at first diagnosis.